Vanzacaftor/Tezacaftor/Ivacaftor deuterated

N/A

Report date: 2026/02/12 20:00:14

Base Information

Drug NameVanzacaftor/Tezacaftor/Ivacaftor deuterated
Drug Alias NameVX-121/tezacaftor/deutivacaftorvanzacaftor tripleVX-121/tezacaftor/VX-561VX-561/tezacaftor/VX-121Deutivacaftor/tezacaftor/vanzacaftor +[12] 
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Deuterated drugs
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator stimulants
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsCystic Fibrosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/12/20
Country/TerritoryCzechiaBelgiumCanada +[24] 
CombinationsYes VanzacaftorTezacaftorIvacaftor deuterated
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesVertex PharmaceuticalVertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (Ireland) Ltd
Inactive CompaniesN/A
Active IndicationsCystic Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipedia